Alpha Omega Wealth Management buys $35,317 stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Alpha Omega Wealth Management scooped up 475 additional shares in AbbVie Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 575 shares of AbbVie Inc which is valued at $35,317.AbbVie Inc makes up approximately 0.03% of Alpha Omega Wealth Management’s portfolio.

AbbVie Inc closed down -0.23 points or -0.38% at $60.7 with 66,79,223 shares getting traded on Wednesday. Post opening the session at $60.93, the shares hit an intraday low of $60.25 and an intraday high of $61.48 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

Other Hedge Funds, Including , Murphy Capital Management Inc reduced its stake in ABBV by selling 2,259 shares or 19.9% in the most recent quarter. The Hedge Fund company now holds 9,092 shares of ABBV which is valued at $558,431. AbbVie Inc makes up approx 0.09% of Murphy Capital Management Inc’s portfolio.Patten Patten Inctn boosted its stake in ABBV in the latest quarter, The investment management firm added 2,905 additional shares and now holds a total of 237,762 shares of AbbVie Inc which is valued at $14,149,217. AbbVie Inc makes up approx 2.00% of Patten Patten Inctn’s portfolio.Hochman Cole Investment Advisors boosted its stake in ABBV in the latest quarter, The investment management firm added 216 additional shares and now holds a total of 39,796 shares of AbbVie Inc which is valued at $2,368,260. AbbVie Inc makes up approx 2.00% of Hochman Cole Investment Advisors’s portfolio.Chelsea Counsel Co reduced its stake in ABBV by selling 2,831 shares or 37.28% in the most recent quarter. The Hedge Fund company now holds 4,762 shares of ABBV which is valued at $278,577. AbbVie Inc makes up approx 0.08% of Chelsea Counsel Co’s portfolio.

On the company’s financial health, AbbVie Inc reported $1.13 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 29, 2016. Analyst had a consensus of $1.12. The company had revenue of $6400.00 million for the quarter, compared to analysts expectations of $6382.82 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.89 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. Societe Generale Initiated AbbVie Inc on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $47.Deutsche Bank Initiated AbbVie Inc on Mar 15, 2016 to “Hold”, Price Target of the shares are set at $63.AbbVie Inc was Upgraded by Citigroup to ” Buy” on Feb 23, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.